MedTrace Logo

A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder

NCT01640002 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-07-13

No results posted yet for this study

Summary

It's a double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to treat overactive bladder (OAB) in HTLV 1 infected patients.

We think that the treatment of the OAB with Propantheline could reduce nocturia and frequency in sixty percent.

Conditions

  • Overactive Bladder Associated With HTLV-1

Interventions

DRUG

Propantheline Bromide

15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.

DRUG

Placebo

PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS

Sponsors & Collaborators

  • Hospital Universitário Professor Edgard Santos

    lead OTHER

Principal Investigators

  • José Abraão Carneiro Neto · Service of Imunology - Universitary Hospital Prof. Edgard Santos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-10-31
Completion
2013-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01640002 on ClinicalTrials.gov